With AGGRASTAT® will be Presented at the PCR e-Course, Late Breaking Trial Sessions, June 27, 2020
WINNIPEG, MB, June 15, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is pleased to announce that on Saturday, June 27, 2020, Dr. Marco Valgimigli, MD, PhD, Professor of Cardiology, Director of Clinical Research at Bern University Hospital, will present the results of the FABOLUS-FASTER Phase 4 clinical trial. The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of primary PCI. Dr. Valgimigli's presentation will take place during a late-breaking trial session at the PCR e-Course 2020, on Saturday, June 27 at 9:00 am CET / 3:00 am EDT.
FABOLUS-FASTER is a randomized, open-label, multi-center trial comparing AGGRASTAT® to cangrelor in patients with ST-elevation myocardial infarction referred for PCI*. A total of 120 subjects were randomized to receive AGGRASTAT®, cangrelor, chewed or integer prasugrel at the beginning of primary PCI.
- Presentation of FABOLUS-FASTER Trial Results by Dr. Marco Valgimigli:
9:00 am CET / 3:00 am EDT on Saturday, June 27 at the PCR e-Course 2020, Late Breaking Trials, Session "STEMI Interventions: First-In-Man and Novel Pharmacological Strategies", virtual meeting. To register and participate in the PCR e-Course, click here: https://www.pcronline.com/Courses/PCR-e-Course
The content will remain available on replay during and after the e-Course.
Complete results from this study have been accepted for publication in Circulation, a peer-reviewed journal of the American Heart Association.
Additional Details About the Study
FABOLUS-FASTER was funded by a grant from Medicure. This study does not imply comparable efficacy, safety, or product interchangeability. *Please note that the use of AGGRASTAT® in STEMI patients has not been approved by the FDA. As of this time, neither AGGRASTAT® nor any of the GP IIb/IIIa inhibitors are indicated for the use in STEMI patients. AGGRASTAT® is approved for use in NSTE-ACS patients. Refer to Important Safety Information below and the U.S. Prescribing Information for complete product information. For additional information about FABOLUS-FASTER, please visit https://clinicaltrials.gov/ct2/show/NCT02978040
About AGGRASTAT®
AGGRASTAT® is an IV antiplatelet medication indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). AGGRASTAT® is currently the most widely used GP IIb/IIIa inhibitor in the U.S.2 and has several administration benefits including room temperature storage, a 3-year shelf life and is available in pre-mixed formats. Please refer to the IMPORTANT SAFETY INFORMATION below.
About Medicure Inc. Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAGTM (pitavastatin) tablets and the ReDS™ device in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure